Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes (META2)
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cisplatin (Primary) ; Cyclophosphamide (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms META2
- 11 Oct 2016 Biomarkers information updated
- 11 Aug 2013 New trial record